- Ticker
- ACTI.ST
- Price
- 1.08
- Stock movement down
- -0.02 (-2.18%)
- Company name
- Active Biotech AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Markedsverdi
- 244.40M
- Ent verdi
- 217.90M
- Pris/omsetning
- -
- Pris/bok
- 7.88
- Utbytte avkastning
- -
- Utbytte vekst
- -
- Vekst år
- -
- FCF-utbetaling
- -
- Etterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års avkastning
- -23.23%
- 3 års avkastning
- -22.78%
- 5 års avkastning
- -16.25%
- 10 års avkastning
- -28.12%
Sist oppdatert: 2022-08-25
UTBYTTE
ACTI.ST betaler ikke utbytte
VERDSETTELSE
Verdsettelsesforhold
Loading...
Verdsettelsesforhold-data
| Etterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Verdsettelse (Salg/Bokført verdi)
Loading...
Verdsettelse (Salg/Bokført verdi) data
| Pris til omsetning | - |
| Pris til bok | 7.88 |
| EV i forhold til salg | - |
ØKONOMI
Per aksje
Loading...
Per aksje-data
| Gjeldende aksje antall | 227.14M |
| EPS (TTM) | -0.24 |
| FCF per aksje (TTM) | -0.23 |
Resultatregnskap
Loading...
Resultatregnskap-data
| Inntekter (TTM) | 0.00 |
| Bruttofortjeneste (TTM) | 0.00 |
| Driftsinntekter (TTM) | -54.20M |
| Netto inntekt (TTM) | -54.40M |
| EPS (TTM) | -0.24 |
| EPS (1 år fremover) | - |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | - |
| Driftsmargin (TTM) | - |
| Fortjenestemargin (TTM) | - |
Balanse
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
| Kontanter | 37.80M |
| Netto fordringer | 3.60M |
| Samlede omløpsmidler | 41.50M |
| Goodwill | 0.00 |
| Immaterielle eiendeler | 0.00 |
| Eiendom, anlegg og utstyr | 0.00 |
| Sum eiendeler | 42.30M |
| Leverandørgjeld | 0.00 |
| Kortsiktig/nåværende langsiktig gjeld | 0.00 |
| Sum kortsiktig gjeld | 11.10M |
| Sum gjeld | 11.30M |
| Aksjonærenes egenkapital | 31.00M |
| Netto varige driftsmidler | 30.80M |
Kontantstrøm
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
| Kontantstrøm fra drift (TTM) | -52.87M |
| Kapitalutgifter (TTM) | 200.00K |
| Fri kontantstrøm (TTM) | -53.07M |
| Utbetalt utbytte (TTM) | 0.00 |
Finansielle inntekter
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
| Egenkapitalavkastning | -175.48% |
| Avkastning på eiendeler | -128.61% |
| Avkastning på investert kapital | -175.48% |
| Kontantavkastning på investert kapital | -171.18% |
AKSJEINFORMASJON
Aksjediagram
Loading...
Aksjekurs-data
| Åpning | 1.05 |
| Daglig høy | 1.10 |
| Daglig lav | 1.05 |
| Daglig volum | 174K |
| Tidenes høyeste | 321.94 |
| 1 år analytikerestimat | 2.40 |
| Beta | 0.75 |
| EPS (TTM) | -0.24 |
| Utbytte per aksje | - |
| Ex-div dato | 17 Apr 1998 |
| Neste dato for resultatpresentasjon | 3 Nov 2022 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ACTI.ST | S&P500 | |
| Nåværende prisfall fra toppnotering | -99.67% | -12.18% |
| Høyeste prisfall | -99.72% | -56.47% |
| Dato for høyeste fall | 8 Mar 2022 | 9 Mar 2009 |
| Gj.snittlig fall fra topp | -91.27% | -11.38% |
| Gj.snittlig tid til ny topp | 6417 days | 12 days |
| Maks tid til ny topp | 6416 days | 1805 days |
SELSKAPSOPPLYSNINGER
Markedsverdi
244.40M
Markedsverdi kategori
Small-cap
Beskrivelse
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Ansatte
9
Nettsted
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
Sweden
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Lund, June 1, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab...
1. juni 2022
The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was carried out through postal voting, without any physical att...
19. mai 2022
Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of mye...
18. mai 2022
Active Biotech's Annual Report 2021 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Download as PDF Lund, April 28, 2022 Active Biotech AB...
28. april 2022
Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotech’s patent related to use of laquinimod ...
26. april 2022
FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01)First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma (Feb 07)Active ...
21. april 2022
The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Thursday, May 19, 2022. Due to the situation resulting from the Corona virus, the M...
20. april 2022
The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company’s incentive program for the company’s employees (Plan 2020/2024). Today, t...
31. mars 2022
The correction refers to the administrative costs for the period January – December 2021 that due to oversight have been stated too low. The incorrect amount was SEK 14,0 M, the correct amount is SEK ...
25. mars 2022
FOURTH QUARTER IN BRIEF In 2021, we made substantial progress in our projects to address unmet medical need in hematological cancers and inflammatory eye disorders. The fourth quarter in particular pr...
9. februar 2022
Neste side